US54948X1090
© PR Newswire
09.12.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
News Preview
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection DeviceReal-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studiesNEW YORK, Dec. 9,...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
News Preview
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digit...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2025
LUCD
LISTED
NASDAQ
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Veris Health launched commercial phase of strategic partnership and
relaunched development of implantable physiological monitor
PAVmed signed letter of intent (LOI) to license groundbreaking endoscopic esophageal imaging technology...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
12.11.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement milestones
Multi-Jurisdictional Contractor Advisory Committ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
25.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
News Preview
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors
NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today ann...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
News Preview
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion
NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
News Preview
NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, i...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
News Preview
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 25,000,000 shares of its common stock at a public offering pr...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
News Preview
NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
News Preview
Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
News Preview
Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT
NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today annou...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
News Preview
Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones
Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for EsoGuard to be held on September 4...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
30.07.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
News Preview
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
LUCD
LISTED
NASDAQ
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
News Preview
Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET
NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that on Thursday, September 4, 2025, fro...
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2025
LUCD
LISTED
NASDAQ
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
News Preview
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network
NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and...
Themefolio
Profiler
Peergroup
© PR Newswire
27.05.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
News Preview
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective a...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
News Preview
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25
Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Conference call and webcast to be held today, May 14th, at 8:30 AM EDT
NEW YORK, May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nas...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
News Preview
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcas...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
LUCD
LISTED
NASDAQ
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
News Preview
Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing
NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive dat...
Themefolio
Profiler
Peergroup
© PR Newswire
11.04.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
News Preview
NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, i...
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
News Preview
NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a public offering pri...
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
News Preview
NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to...
Themefolio
Profiler
Peergroup
© PR Newswire
03.04.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
News Preview
NEW YORK, April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
News Preview
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference
NEW YORK, March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasd...
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase
Recognized EsoGuard revenue of $1.2 million in 4Q24
New sales channel generated over 20 new cash-pay concierge medicine contracts
Secured first agreement to pay for EsoGuard under state biomarker legislation
Conference call and webcast to be held today, Ma...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
News Preview
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy
NEW YORK, March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsi...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
News Preview
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy
NEW YORK, March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (N...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
News Preview
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer
NEW YORK, March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hi...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
News Preview
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcas...
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
News Preview
NEW YORK, March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purc...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
News Preview
NEW YORK, March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of c...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
LUCD
LISTED
NASDAQ
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
News Preview
Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today a...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
News Preview
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received written notification from the Listings Qualifications Department of the Nasdaq Stock Market...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
News Preview
LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics co...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
NEW YORK, Feb. 6, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference b...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
News Preview
Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent
NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced it performed a record numb...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
News Preview
NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LL...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
News Preview
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters
NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
News Preview
New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debt
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
News Preview
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
News Preview
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Servi...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
LUCD
LISTED
NASDAQ
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
News Preview
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage
Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor
Ongoing initiatives position PAVmed...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
News Preview
EsoGuard® revenue up 20 percent sequentially
Clinical evidence package for Medicare coverage submission complete
Direct contracting initiative expanded to multiple programs to drive near-term revenue growth
Conference call and webcast to be held today, November 13th at 8:30 AM EST
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (N...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
News Preview
Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage
NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagno...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
News Preview
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets
NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagno...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
News Preview
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
News Preview
NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim Healthcare Virtual Summit....
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
News Preview
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion
NEW YORK, Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company and several o...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
News Preview
Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing
NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of P...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
LUCD
LISTED
NASDAQ
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
News Preview
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that the American Foregut Society...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
News Preview
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening
NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
News Preview
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters
NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
LUCD
LISTED
NASDAQ
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
News Preview
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Na...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
News Preview
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually
Clinical data now well-positioned for final push towards broad coverage and reimbursement
Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment
Conference call and webcast to be held today, August 12th at 8:...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
LUCD
LISTED
NASDAQ
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
News Preview
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health
NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
